Cargando…

The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma

Long non-coding RNAs (lncRNAs) are an important class of epigenetic regulators involved in both physiological processes and cancer development. Preliminary evidence suggested that lncRNAs could act as accurate prognostic and diagnostic biomarkers. Parathyroid cancer is a rare endocrine neoplasia, wh...

Descripción completa

Detalles Bibliográficos
Autores principales: Morotti, Annamaria, Cetani, Filomena, Passoni, Giulia, Borsari, Simona, Pardi, Elena, Guarnieri, Vito, Verdelli, Chiara, Tavanti, Giulia Stefania, Valenti, Luca, Bianco, Cristiana, Ferrero, Stefano, Corbetta, Sabrina, Vaira, Valentina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108332/
https://www.ncbi.nlm.nih.gov/pubmed/35586620
http://dx.doi.org/10.3389/fendo.2022.869006
_version_ 1784708678835765248
author Morotti, Annamaria
Cetani, Filomena
Passoni, Giulia
Borsari, Simona
Pardi, Elena
Guarnieri, Vito
Verdelli, Chiara
Tavanti, Giulia Stefania
Valenti, Luca
Bianco, Cristiana
Ferrero, Stefano
Corbetta, Sabrina
Vaira, Valentina
author_facet Morotti, Annamaria
Cetani, Filomena
Passoni, Giulia
Borsari, Simona
Pardi, Elena
Guarnieri, Vito
Verdelli, Chiara
Tavanti, Giulia Stefania
Valenti, Luca
Bianco, Cristiana
Ferrero, Stefano
Corbetta, Sabrina
Vaira, Valentina
author_sort Morotti, Annamaria
collection PubMed
description Long non-coding RNAs (lncRNAs) are an important class of epigenetic regulators involved in both physiological processes and cancer development. Preliminary evidence suggested that lncRNAs could act as accurate prognostic and diagnostic biomarkers. Parathyroid cancer is a rare endocrine neoplasia, whose management represents a clinical challenge due to the lack of accurate molecular biomarkers. Our previous findings showed that human parathyroid tumors are characterized by a different lncRNAs signature, suggesting heterogeneity through the different histotypes. Particularly, we found that the lncRNA BC200/BCYRN1 could represent a candidate biomarker for parathyroid carcinomas (PCas). Here we aimed to extend our preliminary data evaluating whether BC200 could be an accurate non-invasive biomarker of PCas to support the clinical management of patients affected by parathyroid tumors at diagnosis, prognosis and follow-up. To provide a non-invasive point-of-care for parathyroid carcinoma diagnosis and follow-up, we analyzed BC200 expression in patients’ serum through digital PCR. Our results show that BC200 counts are higher in serum from patients harboring PCa (n=4) compared to patients with parathyroid adenoma (PAd; n=27). Further, in PAd patients circulating BC200 levels are positively correlated with serum total calcium. Then, we found that BC200 is overexpressed in metastatic PCas (n=4) compared to non-metastatic ones (n=9). Finally, the lncRNA expression in PCa patients’ serum drops are reduced after parathyroidectomy, suggesting its possible use in the post-operative setting for patients follow-up. Overall, these findings extend the knowledge on BC200 in parathyroid tumors, supporting its role as a useful biomarker for management of PCa.
format Online
Article
Text
id pubmed-9108332
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-91083322022-05-17 The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma Morotti, Annamaria Cetani, Filomena Passoni, Giulia Borsari, Simona Pardi, Elena Guarnieri, Vito Verdelli, Chiara Tavanti, Giulia Stefania Valenti, Luca Bianco, Cristiana Ferrero, Stefano Corbetta, Sabrina Vaira, Valentina Front Endocrinol (Lausanne) Endocrinology Long non-coding RNAs (lncRNAs) are an important class of epigenetic regulators involved in both physiological processes and cancer development. Preliminary evidence suggested that lncRNAs could act as accurate prognostic and diagnostic biomarkers. Parathyroid cancer is a rare endocrine neoplasia, whose management represents a clinical challenge due to the lack of accurate molecular biomarkers. Our previous findings showed that human parathyroid tumors are characterized by a different lncRNAs signature, suggesting heterogeneity through the different histotypes. Particularly, we found that the lncRNA BC200/BCYRN1 could represent a candidate biomarker for parathyroid carcinomas (PCas). Here we aimed to extend our preliminary data evaluating whether BC200 could be an accurate non-invasive biomarker of PCas to support the clinical management of patients affected by parathyroid tumors at diagnosis, prognosis and follow-up. To provide a non-invasive point-of-care for parathyroid carcinoma diagnosis and follow-up, we analyzed BC200 expression in patients’ serum through digital PCR. Our results show that BC200 counts are higher in serum from patients harboring PCa (n=4) compared to patients with parathyroid adenoma (PAd; n=27). Further, in PAd patients circulating BC200 levels are positively correlated with serum total calcium. Then, we found that BC200 is overexpressed in metastatic PCas (n=4) compared to non-metastatic ones (n=9). Finally, the lncRNA expression in PCa patients’ serum drops are reduced after parathyroidectomy, suggesting its possible use in the post-operative setting for patients follow-up. Overall, these findings extend the knowledge on BC200 in parathyroid tumors, supporting its role as a useful biomarker for management of PCa. Frontiers Media S.A. 2022-05-02 /pmc/articles/PMC9108332/ /pubmed/35586620 http://dx.doi.org/10.3389/fendo.2022.869006 Text en Copyright © 2022 Morotti, Cetani, Passoni, Borsari, Pardi, Guarnieri, Verdelli, Tavanti, Valenti, Bianco, Ferrero, Corbetta and Vaira https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Endocrinology
Morotti, Annamaria
Cetani, Filomena
Passoni, Giulia
Borsari, Simona
Pardi, Elena
Guarnieri, Vito
Verdelli, Chiara
Tavanti, Giulia Stefania
Valenti, Luca
Bianco, Cristiana
Ferrero, Stefano
Corbetta, Sabrina
Vaira, Valentina
The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma
title The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma
title_full The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma
title_fullStr The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma
title_full_unstemmed The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma
title_short The Long Non-Coding BC200 Is a Novel Circulating Biomarker of Parathyroid Carcinoma
title_sort long non-coding bc200 is a novel circulating biomarker of parathyroid carcinoma
topic Endocrinology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9108332/
https://www.ncbi.nlm.nih.gov/pubmed/35586620
http://dx.doi.org/10.3389/fendo.2022.869006
work_keys_str_mv AT morottiannamaria thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT cetanifilomena thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT passonigiulia thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT borsarisimona thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT pardielena thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT guarnierivito thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT verdellichiara thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT tavantigiuliastefania thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT valentiluca thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT biancocristiana thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT ferrerostefano thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT corbettasabrina thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT vairavalentina thelongnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT morottiannamaria longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT cetanifilomena longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT passonigiulia longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT borsarisimona longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT pardielena longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT guarnierivito longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT verdellichiara longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT tavantigiuliastefania longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT valentiluca longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT biancocristiana longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT ferrerostefano longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT corbettasabrina longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma
AT vairavalentina longnoncodingbc200isanovelcirculatingbiomarkerofparathyroidcarcinoma